NASDAQ
0.91USD
+0.07 (+7.78%)
We have scored 10 news catalysts on 22nd Century Group, Inc. (XXII) over the past 12 months. The biggest single-day move next to one of them came Sep 24, 2026, when XXII closed −35.5%: “Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket”. Coverage across the window leans positive (average ticker sentiment +0.10). Most of the impact sits in sector consumer and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
315.4K
P/E
—
EPS
—
Beta
0.61
52W range
0.785-540
Day range
0.85–0.94
Open
0.88
Prev close
0.85
Volume
120.1K
Avg volume
79.2K
Dividend
0.00
IPO
2011-01-26
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about 22nd Century Group, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for XXII: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.
